Lymphatic Imaging, Genomic, and pHenotyping Technologies (LIGHT) Program | ARPA H SOL 24 102

Opportunity Information: Apply for ARPA H SOL 24 102

The Lymphatic Imaging, Genomic, and pHenotyping Technologies (LIGHT) Program is a federal research and development funding opportunity from the Advanced Research Projects Agency for Health (ARPA-H). It is published as a discretionary grant competition under Funding Opportunity Number ARPA H SOL 24 102 and is categorized under Science and Technology and other Research and Development (CFDA 93.384). The program, as framed by its title, is oriented toward advancing enabling technologies and integrated approaches that improve how the lymphatic system can be measured, visualized, characterized, and linked to molecular and phenotypic data. In practical terms, the opportunity is positioned to support ambitious, technology-forward work that brings together lymphatic imaging methods, genomic or other molecular profiling capabilities, and robust phenotyping tools so that lymphatic structure and function can be studied with greater resolution, accuracy, and clinical relevance.

ARPA-H is using a Cooperative Agreement as the funding instrument. That matters because a cooperative agreement typically involves substantial federal involvement during the project period compared with a standard grant. Applicants should generally expect an active program management style, including technical milestones, frequent progress reviews, and adaptive project execution. For teams pursuing complex technology development, validation, and translation pathways, the cooperative agreement structure often aligns with milestone-driven plans, iterative prototyping, and coordinated testing across partners, which is consistent with the kind of high-impact, high-urgency technology development ARPA-H is known to support.

Eligibility is listed as unrestricted, which means the competition is broadly open rather than limited to a narrow applicant class. In many ARPA-H opportunities, this effectively allows a wide range of organizations to apply, including universities, nonprofit research institutes, small and large businesses, and other entities that can assemble the technical and operational capability to deliver advanced R&D outcomes. Because the topic spans imaging technology, genomics, and phenotyping, competitive teams are likely to be multidisciplinary, often combining biomedical engineering, imaging physics, computational biology, assay development, clinical research operations, and data science. Even without the attached full text, the title strongly suggests that proposals that integrate these domains into a coherent platform, workflow, or set of interoperable tools would fit the program intent better than isolated, single-modality advances.

Key administrative details from the listing are straightforward. The opportunity was created on 2024-06-11 with an original closing date of 2024-06-27, indicating a relatively short submission window typical of some ARPA-H solicitations. The listing does not provide an award ceiling or expected number of awards in the extracted fields, so the funding range, project duration, and anticipated portfolio size would need to be confirmed in the attached funding opportunity documents. Likewise, the short description in the record simply states "See attached funding opportunity," which means the essential technical objectives, program structure (for example, whether it is organized into technical areas, phases, or performer teams), deliverables, data-sharing expectations, and evaluation criteria are contained in the attachment rather than in the summary metadata.

At a high level, the LIGHT Program can be understood as seeking breakthroughs that make the lymphatic system easier to interrogate in living systems and easier to connect to underlying biology and observed outcomes. Imaging improvements could involve new contrast approaches, higher sensitivity or resolution, better quantification, or more practical clinical workflows. Genomic components could encompass DNA, RNA, single-cell or spatial profiling, or other molecular readouts that explain lymphatic behavior across conditions. Phenotyping technologies could include digital biomarkers, functional assessments, high-dimensional clinical measurements, or computational methods that translate raw measurements into actionable phenotypes. The most compelling outcomes for a program like this typically include standardized measurement pipelines, validated datasets, and tools that can be adopted beyond a single lab, enabling downstream research and potentially future clinical translation.

In short, this ARPA-H solicitation is a cooperative-agreement R&D opportunity aimed at accelerating next-generation technologies and integrated systems for lymphatic imaging, genomic characterization, and phenotyping, with broad eligibility and a tight timeline based on the posted dates. The definitive scope, technical requirements, submission components, and review factors are in the attached funding opportunity document referenced by the notice.

• The Advanced Research Projects Agency for Health in the science and technology and other research and development sector is offering a public funding opportunity titled "Lymphatic Imaging, Genomic, and pHenotyping Technologies (LIGHT) Program" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.384.
• This funding opportunity was created on 2024-06-11.
• Applicants must submit their applications by 2024-06-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Unrestricted.

Apply for ARPA H SOL 24 102

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: